$24.6 billion of the global biotech industry’s turnover of $120 billion is based on products that originated in Israeli research

Israeli inventions underpin 20% of global biotech revenue

Pitango general partner Ruth Alon: $24.6 billion of the global biotech industry’s turnover of $120 billion is based on products that originated in Israeli research.

6 June 13 21:10, Gali Weinreb

Israel’s life sciences industry is manic-depressive. One moment, it’s preparing for catastrophe and pending collapse, and the next, it’s celebrating the industry’s hoped-for breakthrough. There is no argument that Israel’s science and medicine are outstanding, and there is the feeling that the growth of a thriving pharmaceutical industry is only a matter of time. But it is not easy to translate the vision into reality.

“If we examine how many products in the world are based on Israeli technology, we discover that the vision has already been partly realized,” saysPitango Venture Capital general partner Ruth Alon, who handles the firm’s life sciences business, and is chairwoman of the IATA BioMed 2013 Conference.Alon found that 20.5% of the global biotech industry’s turnover – $24.6 billion out of $120 billion – is based on products that originated in Israeli research. This figure does not include several very important products by Israeli researchers who are currently abroad. It also excludes products developed through the use of so-called “Kvili patents” for the production of monoclonal antibodies developed by Prof. Shmuel Kvili.

In the pharmaceutical (chemical, not biological drugs) industry, the situation is slightly different, but here too, there is room for pride. Products originating in Israel account for 0.7% of the global industry.

In the medical devices industry, Israeli industry has already proven that it is strong enough to attract leading foreign companies. Israeli products account for 1% of the $350 billion global medical devices turnover. Some of this figure is Israeli exports. Israel is also a major player in the medical imaging industry.

“When I collated the data about all the medical products which should carry the label ‘Israel Inside’, a picture emerges that we can be proud of: Israeli academe has made a major contribution to the improvement of human health,” says Alon. “Shouldn’t we use at least some of these capabilities to create a large and important industry, instead of a string of exits?” she asks.

That is still an open question.

Unknown's avatarAbout bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (www.heroinnovator.com), the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a comment